PD-1 Drug Safety Information: PMDA Adds Warning for Nivolumab

• November 24, 2015
• Reading time: 1 minute

Information as of November 24, 2015:

Japan's PMDA (Pharmaceuticals and Medical Devices Agency / 独立行政法人 医薬品医療機器総合機構) has added new precautions to the prescribing information for nivolumab.

[Type 1 Diabetes] Patients with Type 1 diabetes (including fulminant Type 1 diabetes mellitus, FT1DM) may develop diabetic ketoacidosis. Symptoms include thirst, nausea, vomiting, or elevated blood glucose — please monitor carefully. If Type 1 diabetes is suspected, discontinue use and initiate appropriate management such as insulin therapy.

Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).

Figure 1

Figure 2

Figure 3

Figure 4